CL2011001944A1 - Metodo de diagnostico in vitro de un sujeto con sindrome de intestino irritable (ibs). - Google Patents

Metodo de diagnostico in vitro de un sujeto con sindrome de intestino irritable (ibs).

Info

Publication number
CL2011001944A1
CL2011001944A1 CL2011001944A CL2011001944A CL2011001944A1 CL 2011001944 A1 CL2011001944 A1 CL 2011001944A1 CL 2011001944 A CL2011001944 A CL 2011001944A CL 2011001944 A CL2011001944 A CL 2011001944A CL 2011001944 A1 CL2011001944 A1 CL 2011001944A1
Authority
CL
Chile
Prior art keywords
ibs
subject
develop
cdtb
likelihood
Prior art date
Application number
CL2011001944A
Other languages
English (en)
Inventor
Mark Pimentel
Christopher Chang
Original Assignee
Cedars Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42562061&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2011001944(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cedars Sinai Medical Center filed Critical Cedars Sinai Medical Center
Publication of CL2011001944A1 publication Critical patent/CL2011001944A1/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/121—Helicobacter (G); Campylobacter (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/24—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/24—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • G01N2333/25—Shigella (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G01N2333/922—Ribonucleases (RNAses); Deoxyribonucleases (DNAses)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

UN METODO IN VITRO QUE COMPRENDE OBTENER UNA MUESTRA BIOLÓGICA DE UN SUJETO QUE TIENE UN SÍNTOMA DE SÍNDROME DE INTESTINO IRRITABLE (IBS) Y ES SELECCIONADO DEL GRUPO QUE CONSISTE EN UN SUJETO QUE NECESITA UN DIAGNOSTICO RELACIONADO CON EL SÍNDROME E INTESTADO IRRITABLE (IBS) UN SUJETO QUE NECESITA UN DIAGNOSTICO RELACIONADO CON UN SUBGRUPO DE IBS UN SUJETO QUE NECESITA UNA DETERMINACIÓN DE PROBABILIDAD DE TENER O DESARROLLAR IBS Y/O UN SUJETO QUE NECESITA UNA DETERMINACIÓN DE PROBABILIDAD DE TENER O DESARROLLAR UN SUBGRUPO DE IBS DETECTAR LA PRESENCIA O AUSENCIA DE UN ANTICUERPO CAPAZ DE UNIRSE ESPECÍFICAMENTE A CDTB O UN FRAGMENTO DE LOS MISMOS EN LA MUESTRA BIOLÓGICA CORRELACIONAR LA PRESENCIA DEL ANTICUERPO CAPAZ DE UNIRSE ESPECÍFICAMENTE A CDTB O UN FRAGMENTO DE LOS MISMOS CON UNA PRESENCIA PROBABLE DE IBS UNA PRESENCIA PROBABLE DE UN SUBGRUPO DE IBS PROBABILIDAD DE TENER O DESARROLLAR IBS Y/O PROBABILIDAD DE TENER O DESARROLLAR UN SUBGRUPO DE IBS CORRELACIONAR LA AUSENCIA DEL ANTICUERPO CAPAZ DE UNIRSE ESPECÍFICAMENTE A CDTB O UN FRAGMENTO DE LOS MISMOS CON UNA AUSENCIA PROBABLE DE IBS UNA AUSENCIA PROBABLE DEL SUBGRUPO DE IBS MENOR PROBABILIDAD DE TENER O DESARROLLAR IBS Y/O TENER O DESARROLLAR UN SUBGRUPO DE IBS.
CL2011001944A 2009-02-11 2011-08-10 Metodo de diagnostico in vitro de un sujeto con sindrome de intestino irritable (ibs). CL2011001944A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15177909P 2009-02-11 2009-02-11
US28625009P 2009-12-14 2009-12-14

Publications (1)

Publication Number Publication Date
CL2011001944A1 true CL2011001944A1 (es) 2012-02-03

Family

ID=42562061

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011001944A CL2011001944A1 (es) 2009-02-11 2011-08-10 Metodo de diagnostico in vitro de un sujeto con sindrome de intestino irritable (ibs).

Country Status (10)

Country Link
US (5) US9110081B2 (es)
EP (2) EP3349004A1 (es)
AU (2) AU2010213708B2 (es)
CA (1) CA2752033C (es)
CL (1) CL2011001944A1 (es)
DK (1) DK2396652T3 (es)
ES (1) ES2656850T3 (es)
MX (2) MX348670B (es)
NO (1) NO2396652T3 (es)
WO (1) WO2010093801A1 (es)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9702884B2 (en) 2012-09-17 2017-07-11 Cedars-Sinai Medical Center Methods for detecting the presence of irritable bowel syndrome and system for diagnosing same
US10132814B2 (en) 2014-10-09 2018-11-20 Cedars-Sinai Medical Center Methods for distinguishing irritable bowel syndrome from inflammatory bowel disease and celiac disease
US10151752B2 (en) 2009-02-11 2018-12-11 Cedars-Sinai Medical Center Antibody to cytolethal distending toxin of Campylobacter jejuni
US10352944B2 (en) 2013-10-09 2019-07-16 Cedars-Sinai Medical Center Method of determinig levels of anti-vinculin and anti-cytolethal distending toxin antibodies in subjects desiring to distinguish irritable bowel syndrome from inflammatory bowel disease
RU2803008C1 (ru) * 2023-05-03 2023-09-05 Наталья Юрьевна Пшеничная Способ прогнозирования риска развития синдрома раздраженного кишечника у больных после перенесенной острой диареи бактериальной этиологии и выбора тактики лечения

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11693009B2 (en) 2009-02-11 2023-07-04 Cedars-Sinai Medical Center Methods for detecting post-infectious irritable bowel syndrome
CN102507949B (zh) * 2011-11-15 2013-12-25 吉林出入境检验检疫局检验检疫技术中心 液相芯片检测金黄色葡萄球菌的方法
CN102426233B (zh) * 2011-11-15 2013-12-04 吉林出入境检验检疫局检验检疫技术中心 液相芯片检测空肠弯曲菌的方法
AR089797A1 (es) * 2012-01-27 2014-09-17 Merck Sharp & Dohme Vacunas contra clostridum difficile que comprenden toxinas recombinantes
GB201223342D0 (en) * 2012-12-23 2013-02-06 Glaxosmithkline Biolog Sa Immunogenic composition
EP3573650A4 (en) 2017-01-30 2020-12-09 Cedars-Sinai Medical Center DIAGNOSIS OF SCLERODERMIA
CN111793130B (zh) * 2019-03-20 2021-09-14 华中农业大学 一株副猪嗜血杆菌CdtB杂交瘤细胞及单克隆抗体应用
EP3913371A1 (en) 2020-05-18 2021-11-24 Neuroimmun GmbH Method and kit for diagnosting irritable bowel syndrome and for its relief through dietary interventions

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
CA2090220C (en) 1990-10-22 2003-07-08 Thomas Julius Borody Treatment of non-inflammatory and non-infectious bowel disorders
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5691151A (en) 1994-10-07 1997-11-25 Regents Of University Of California Methods of screening for ulcerative colitis and crohn's disease by detecting VH3-15 autoantibody and panca
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
FR2806805A1 (fr) 2000-03-22 2001-09-28 Centre Nat Rech Scient SEQUENCE PEPTIDIQUES COMPRENANT UN OU PLUSIEURS MOTIFS DE LIAISON AUX PROTEINES DE LA FAMILLE Ena/VASP, ET LEURS UTILISATIONS
US20030157159A1 (en) 2002-01-15 2003-08-21 Franklin Lanny Udell Prevention and treatment of digestive tract infections
WO2003097854A2 (en) 2002-05-17 2003-11-27 Sugen, Inc. Novel biomarkers of tyrosine kinase inhibitor exposure and activity in mammals
US20040106590A1 (en) 2002-08-29 2004-06-03 Barry Eisenstein Methods and reagents for treating infections of clostridium difficile and diseases associated therewith
US7595386B2 (en) * 2003-01-24 2009-09-29 William Beaumont Hospital Methods and compositions for heat activated gene therapy using cytolethal distending toxin
ATE491953T1 (de) 2003-09-15 2011-01-15 Oklahoma Med Res Found Verfahren zur verwendung von cytokintests zur diagnose, behandlung und beurteilung von ankyloider spondylitis
WO2005054472A1 (ja) * 2003-12-05 2005-06-16 Fuso Pharmaceutical Industries, Ltd. 細胞膨張化致死毒およびそれを標的としたカンピロバクター属に属する細菌の検出
US20090233888A1 (en) 2005-03-23 2009-09-17 Usc Stevens, University Of Southern California Treatment of disease conditions through modulation of hydrogen sulfide produced by small intestinal bacterial overgrowth
SI2054066T1 (sl) 2006-08-02 2015-08-31 Salix Pharmaceuticals, Inc. Postopki za zdravljenje radiacijskega enteritisa
EP2102367A2 (en) 2006-11-09 2009-09-23 XDX, Inc. Methods for diagnosing and monitoring the status of systemic lupus erythematosus
WO2009008005A1 (en) 2007-07-06 2009-01-15 Lupin Limited Pharmaceutical compositions of rifaximin
BRPI0908026B8 (pt) 2008-02-26 2021-05-25 Salix Pharmaceuticals Ltd uso de rifaximina no tratamento de doenças do intestino
ES2529060T3 (es) 2008-11-24 2015-02-16 Cedars-Sinai Medical Center Derivados antioxidantes de la camptotecina y nanoesferas antineoplásicas antioxidantes de los mismos
WO2010093776A1 (en) 2009-02-11 2010-08-19 Cedars-Sinai Medical Center Antibiotic therapy to reduce the likelihood of developing post-infectious irritable bowel syndrome
ES2656850T3 (es) 2009-02-11 2018-02-28 Cedars-Sinai Medical Center Diagnóstico del síndrome intestinal inflamatorio con base en la toxina de distensión citoletal
RU2397178C1 (ru) 2009-02-27 2010-08-20 Федеральное государственное учреждение науки "Центральный научно-исследовательский институт эпидемиологии" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека Диагностическая тест-система в формате иммуночипа и способ серологической дифференциальной диагностики сифилиса
GB201017520D0 (en) 2010-10-15 2010-12-01 Sense Proteomic Ltd Biomarkers
GB201317713D0 (en) 2013-10-07 2013-11-20 Creo Medical Ltd Electrosurgical device
RU2683781C2 (ru) 2013-10-09 2019-04-02 Седарс-Синаи Медикал Сентер Диагностика и лечение синдрома раздраженного кишечника и воспалительного заболевания кишечника
NZ730490A (en) 2014-10-09 2021-07-30 Cedars Sinai Medical Center Methods and systems for distinguishing irritable bowel syndrome from inflammatory bowel disease and celiac disease
EP3573650A4 (en) 2017-01-30 2020-12-09 Cedars-Sinai Medical Center DIAGNOSIS OF SCLERODERMIA

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10151752B2 (en) 2009-02-11 2018-12-11 Cedars-Sinai Medical Center Antibody to cytolethal distending toxin of Campylobacter jejuni
US10527621B2 (en) 2009-02-11 2020-01-07 Cedars-Sinai Medical Center Antibody to cytolethal distending toxin of Campylobacter jejuni
US9702884B2 (en) 2012-09-17 2017-07-11 Cedars-Sinai Medical Center Methods for detecting the presence of irritable bowel syndrome and system for diagnosing same
US9952223B2 (en) 2012-09-17 2018-04-24 Cedars-Sinai Medical Center Method for detecting anti-vinculin antibodies in a subject with an IBS symptom
US10466254B2 (en) 2012-09-17 2019-11-05 Cedars-Sinai Medical Center Method of measuring a level of anti-vinculin antibodies in a biological sample
US10352944B2 (en) 2013-10-09 2019-07-16 Cedars-Sinai Medical Center Method of determinig levels of anti-vinculin and anti-cytolethal distending toxin antibodies in subjects desiring to distinguish irritable bowel syndrome from inflammatory bowel disease
US10132814B2 (en) 2014-10-09 2018-11-20 Cedars-Sinai Medical Center Methods for distinguishing irritable bowel syndrome from inflammatory bowel disease and celiac disease
RU2803008C1 (ru) * 2023-05-03 2023-09-05 Наталья Юрьевна Пшеничная Способ прогнозирования риска развития синдрома раздраженного кишечника у больных после перенесенной острой диареи бактериальной этиологии и выбора тактики лечения

Also Published As

Publication number Publication date
US10151752B2 (en) 2018-12-11
US20200271650A1 (en) 2020-08-27
US9869676B2 (en) 2018-01-16
DK2396652T3 (da) 2018-01-29
CA2752033A1 (en) 2010-08-19
MX2011008355A (es) 2011-09-06
AU2016201529A1 (en) 2016-03-24
CA2752033C (en) 2020-03-24
US20190178890A1 (en) 2019-06-13
EP3349004A1 (en) 2018-07-18
EP2396652B1 (en) 2017-12-13
NO2396652T3 (es) 2018-05-12
AU2016201529B2 (en) 2018-03-08
US9110081B2 (en) 2015-08-18
AU2010213708A1 (en) 2011-08-25
EP2396652A1 (en) 2011-12-21
MX383424B (es) 2025-03-14
EP2396652A4 (en) 2014-11-19
US20110305704A1 (en) 2011-12-15
US10527621B2 (en) 2020-01-07
AU2010213708B2 (en) 2015-12-10
ES2656850T3 (es) 2018-02-28
MX348670B (es) 2017-06-23
US20180231551A1 (en) 2018-08-16
WO2010093801A1 (en) 2010-08-19
US20160061837A1 (en) 2016-03-03

Similar Documents

Publication Publication Date Title
CL2011001944A1 (es) Metodo de diagnostico in vitro de un sujeto con sindrome de intestino irritable (ibs).
PE20160882A1 (es) Diagnostico y tratamiento del sindrome del intestino irritable y la enfermedad inflamatoria intestinal
MX2018002400A (es) Receptores de antigenos quimericos condicionalmente activos para celulas t modificadas.
MX355020B (es) Biomarcadores de cancer de pulmon y usos de los mismos.
MX374652B (es) Ensayos para detectar la presencia o la cantidad de un anticuerpo antifármaco.
MX2013001042A (es) Biomarcadores de cancer pancreatico y usos de los mismos.
CR9635A (es) Deteccion de un antigeno diana independientemente de la presencia o ausencia de un anticuerpo terapeutico correspondiente
BRPI0814250B8 (pt) dispositivo, kit e método para captura e detecção de antígeno de ancilóstomo
MX2018008421A (es) Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias.
CO2019008390A2 (es) Uso de biomarcadores en la identificación de pacientes con cáncer que serán sensibles al tratamiento con un inhibidor de prmt5.
PH12012500850A1 (en) Methods for diagnosing irritable bowel syndrome
MX367046B (es) Marcadores especificos de via para diagnosticar sindrome del intestino irritable.
MX364410B (es) Metodo para detectar nucleosomas que contienen nucleotidos.
MX2019008970A (es) Ensayos de socio de unión específico de plasmón basados en solución y nanoestructuras metálicas.
MX2019002918A (es) Biomarcadores de metabolitos para enfermedades asociadas con el sistema de activacion por contacto.
CR20110567A (es) Dispositivos para diagnostico y metodos relacionados
ES2721907T3 (es) Métodos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal
MX358772B (es) Metodo para detectar cancer.
MX2014004860A (es) Biomarcadores de cancer de pulmon y usos de los mismos.
CO2018004289A2 (es) Inmunoensayo para detectar quininógeno escindido de alto peso molecular
AR087363A1 (es) Uso del anticuerpo i-3859 para la deteccion y diagnostico de los canceres
MX2016014329A (es) Microbiota ibs y sus usos.
CO2021008770A2 (es) Anticuerpos monoclonales específicos para la proteína quimérica l del virus de la parainfluenza humana (piv), secuencias nucleotídicas; método y kit de diagnóstico de infección producida por piv
ES2684758T3 (es) Procedimiento para diagnosticar fibrosis hepática
ES2544984T3 (es) Detección de la descomposición de enzimas en un elemento de ensayo por liberación controlada de un analito protegido